Search Results
Your search for all items matches 34738 pages
Showing 16401 - 16450Maintenance Olaparib in Newly Diagnosed Advanced Ovarian Cancer
As reported in The New England Journal of Medicine by Moore et al, the phase III SOLO-1 trial has shown that maintenance with olaparib, following complete or partial response to platinum-based chemotherapy, significantly prolonged progression-free survival vs placebo in...
Negative Colonoscopy and Long-Term Risk of Colorectal Cancer
Ten years after a negative colonoscopy, patients who were rescreened for colorectal cancer had a lower risk of being diagnosed with and were less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study published by Lee et al...
New Study Examines Orphan Drug Exclusivity and Pricing
A new report commissioned by the National Organization for Rare Disorders (NORD) and published by the IQVIA Institute demonstrates that the 7-year market exclusivity granted to drugs designated under the Orphan Drug Act of 1983 for rare diseases is working as intended. In nearly every case, orphan...
Factors Influencing Response to Pembrolizumab in Various Advanced Cancers
In an analysis from the phase Ib KEYNOTE-028 trial reported in the Journal of Clinical Oncology, Ott et al found that response to pembrolizumab across different cancers was more likely in patients with higher tumor mutational burden, T-cell–inflamed gene-expression profile, and programmed...
Transformation of EGFR-Mutant NSCLC to SCLC
In a study reported in the Journal of Clinical Oncology, Marcoux et al provided further evidence that EGFR-mutant non–small cell lung cancer (NSCLC) can undergo transformation to small cell lung cancer (SCLC) and identified factors associated with such transformation. It has been estimated...
Facing Death: Having the Difficult Conversation With Your Patients
Michael Becker, a former CEO for two biotechnology companies, discusses his terminal head and neck cancer diagnosis and his message for oncologists: be proactive and, at the appropriate time, talk with your patients about death and dying. For more information about Michael Becker’s blog and his HPV ...
FDA Expands Indication for Dasatinib to Pediatric Patients With Ph+ ALL in Combination With Chemotherapy
On January 2, the U.S. Food and Drug Administration (FDA) expanded the indication for dasatinib (Sprycel) tablets to include the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in...
Association Between Systemic Lupus Erythematosus and Cancer Risk
New research published by Song et al in Arthritis Research & Therapy evaluated the link between lupus and cancer risk, supporting the data from earlier studies. The newer study indicates an association between systemic lupus erythematosus (SLE) and increased risk for several cancers (blood,...
Study Assesses Impact of Digital Mammography on Breast Cancer Detection and Recall Rates
The shift from film to digital mammography increased the detection of breast cancer overall in the United Kingdom—without increasing the recall rate—according to a study published by Blanks et al in Radiology. “Image quality with digital mammography is improved over that of...
Lenalidomide Maintenance vs Observation in Newly Diagnosed Multiple Myeloma
In a UK phase III trial (Myeloma XI) reported in The Lancet Oncology, Jackson et al found that lenalidomide maintenance was associated with improved progression-free survival but not overall survival among patients with newly diagnosed multiple myeloma with at least minimal response to induction...
Sorafenib in Progressive, Symptomatic, or Recurrent Desmoid Tumors
In a phase III trial reported in The New England Journal of Medicine, Gounder et al found that sorafenib improved progression-free survival vs placebo in patients with progressive, symptomatic, or recurrent desmoid tumors. As noted by the investigators, there is no current standard of care for...
Time to Biochemical Failure as Surrogate Endpoint in Locally Advanced Prostate Cancer
As reported in the Journal of Clinical Oncology by Dignam et al, analysis of outcomes in the phase III NRG/RTOG 9202 trial indicates that the time interval to biochemical failure (IBF) could serve as a surrogate endpoint for clinical outcomes in patients receiving radiotherapy plus long-term...
Pilot Study of Intratumoral G100 in Merkel Cell Carcinoma
Multiple recent reports have addressed the activity of programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab and avelumab, in Merkel cell carcinoma. However, approximately half of all patients who receive these agents do not maintain a persistent response. In an...
High Long-Term Risk of Solid Cancers in Survivors of Childhood Hodgkin Lymphoma
A new study may bolster existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. The study showed that certain subgroups of patients have an especially high risk. Published by Holmqvist et al in the journal...
Regorafenib vs Lomustine in Relapsed Glioblastoma
In the Italian phase II REGOMA trial reported in The Lancet Oncology, Lombardi et al found that regorafenib was associated with improved overall survival vs lomustine in patients with relapsed glioblastoma. In the open-label trial, 119 patients from 10 Italian sites were randomly assigned between...
RADAR Trial: Short- vs Intermediate-Term Androgen Suppression and Zoledronic Acid in Locally Advanced Prostate Cancer
As reported by Denham et al in The Lancet Oncology, 10-year results of the phase III TROG 03.04 RADAR trial have shown that 18 months of androgen suppression plus radiotherapy is more effective than 6 months of androgen suppression plus radiotherapy in locally advanced prostate cancer, but no...
Adjuvant FOLFIRINOX vs Gemcitabine in Pancreatic Cancer
In a phase III Canadian and French trial reported in The New England Journal of Medicine, Conroy and colleagues in the Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group found that adjuvant modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) produced better...
FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria
On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ravulizumab-cwvz (Ultomiris) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias....
FDA Approves Tagraxofusp-ezrs for Blastic Plasmacytoid Dendritic Cell Neoplasm
On December 21, the U.S. Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years and older. “Prior to [this] approval, there had been no...
ASCO and ESMO Publish Joint Assessment of Their Value Frameworks
TO BETTER UNDERSTAND the performance characteristics of ASCO’s Value Framework Net Health Benefit Score version 2 (ASCO-NHB v2)1 and the European Society for Medical Oncology’s (ESMO’s) Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1),2 ASCO and ESMO undertook a joint project to...
Louis M. Weiner, MD, Named National Academy of Inventors Fellow
THE NATIONAL ACADEMY OF INVENTORS (NAI) has named Louis M. Weiner, MD, Director of the Georgetown Lombardi Comprehensive Cancer Center, to its 2018 class of fellows. According to the National Academy of Inventors, election to NAI Fellow status is the “highest professional distinction accorded to...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
I Welcome Being the Face of Multiple Myeloma
Thirteen years ago, at age 34, I was healthy and enjoying life. I went to the gym almost daily, and when I wasn’t at the gym, I was shooting hoops with my friends. During a gym workout while on a family vacation, I suddenly felt excruciating pain in my left shoulder and thought I must have strained ...
ASCO Remembers Charles A. Coltman, Jr, MD, FASCO, Cooperative Trial Pioneer and ASCO Past President
ASCO AND THE ONCOLOGY COMMUNITY mourn the loss of ASCO Past President and former SWOG leader Charles A. Coltman, Jr, MD, FASCO, President Emeritus, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio. Dr. Coltman died on November 28 at the age of 88....
For Maria Papaleontiou, MD, Research Holds the Key to Improving Care of Patients With Thyroid Cancer
Maria Papaleontiou, MD, whose research interests focus on the complex issues surrounding the management of thyroid cancer and thyroid disease in general, was born on Cyprus, a small island nestled in the azure waters of the Mediterranean Sea. She recently spoke with The ASCO Post about her life and ...
Immune Checkpoint Blockade and Tumor-Specific Vaccine for Incurable HPV16-Related Cancer
In a single-center phase II study reported in JAMA Oncology, Erminia Massarelli, MD, and colleagues found combining tumor-specific vaccine and nivolumab (Opdivo) showed evidence of activity in incurable human papillomavirus (HPV) 16–related cancer. The therapeutic vaccine, ISA 101, induces...
Postoperative Outcomes With Screening- vs Nonscreening-Detected Colorectal Cancers
In a Dutch study reported in JAMA Surgery, Michael P.M. de Neree tot Babberich, MD, of the Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, and colleagues found that postoperative outcomes were better in patients with colon cancer, but not rectal cancer, detected...
Fecal Microbiota Transplantation May Help Restore Beneficial Bacteria in Patients With Cancer
Researchers have shown that autologous fecal microbiota transplantation may be a safe and effective way to help replenish beneficial gut bacteria in patients with cancer who require intense antibiotics during allogeneic hematopoietic stem cell transplantation. Their findings were published by Ying ...
Anil K. Rustgi, MD, Named Director of Herbert Irving Comprehensive Cancer Center
ANIL K. RUSTGI, MD, has been named Director of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and NewYork-Presbyterian/Columbia University Irving Medical Center. Pending approval of the university’s trustees, Dr. Rustgi will serve as Professor of...
Stories of the Scientists Behind Immunotherapy
As the field of immunotherapy accelerates, so does the literature reporting on the path ahead. One of the newer books on the topic is A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. It has a top-notch pedigree: the author, Neil Canavan, is a seasoned journalist with more than ...
Breakthrough Therapy Designation for Brentuximab Vedotin in Front-Line Treatment of Peripheral T-Cell Lymphomas
THE FDA recently granted Breakthrough Therapy designation to brentuximab vedotin (Adcetris) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in ...
Priority Review for Quizartinib in Relapsed or Refractory FLT3-ITD–Positive AML
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) accepted a new drug application and granted Priority Review to quizartinib, a FLT3 inhibitor, for the treatment of adult patients with relapsed or refractory FLT3-ITD–positive acute myeloid leukemia (AML). The FDA is expected to make a decision on...
Welcome Questions About Cervical Cancer Treatment Options
TWO STUDIES reported in The New England Journal of Medicine1,2 showed that patients with early-stage cervical cancer had reduced disease-free and overall survival when treated with minimally invasive radical hysterectomy vs open or radical hysterectomy. The findings of these studies have been...
Comparing Survival Outcomes With Minimally Invasive and Open Surgical Approaches to Early-Stage Cervical Cancer
MINIMALLY INVASIVE radical hysterectomy for women with early-stage cervical cancer has been associated with reduced rates of disease-free and overall survival in the phase III LACC randomized noninferiority trial comparing minimally invasive and open abdominal radical hysterectomy. The results...
New Report Demonstrates Cost of Blood Cancer Care
THE COSTS to treat blood cancer are higher than the costs to treat other cancers, and the costs incurred by a patient diagnosed with a blood cancer do not return to precancer levels, according to a Milliman study commissioned by The Leukemia & Lymphoma Society (LLS). The study—The Cost Burden...
Pembrolizumab in Sorafenib-Pretreated Hepatocellular Carcinoma
ON NOVEMBER 9, 2018, pembrolizumab (Keytruda) was granted accelerated approval for treatment of patients with hepatocellular carcinoma previously treated with sorafenib (Nexavar).1,2 Supporting Efficacy Data APPROVAL WAS BASED on durable responses in the phase II KEYNOTE-224 trial...
Venetoclax in Combination Regimens for Older Patients With AML or Those With Comorbidities Precluding Intensive Induction
On November 21, 2018, venetoclax (Venclexta) was granted accelerated approval for use in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged ≥ 75 years or who have comorbidities that preclude the use of ...
New Year, New Resolutions: Help Your Patients Make Healthy Lifestyle Choices
The Managing Your Weight After a Cancer Diagnosis and the Quitting Tobacco Use After a Cancer Diagnosis booklets from ASCO Answers are the best companions for your patients’ New Year’s resolutions. These resources will help patients to achieve their goals by providing practical tips and strategies...
Managing the Cost of Cancer Care
A cancer diagnosis is often overwhelming. Adding financial burden to the mix can sometimes feel unmanageable. Provide your patients with practical guidelines with the Managing the Cost of Cancer Care booklet from ASCO. It covers health insurance benefits, information about the Affordable Care Act,...
ASCO Resolutions on Step Therapy, Competitive Acquisition Program Proposed at AMA House of Delegates
During this year’s interim meeting of the American Medical Association (AMA) House of Delegates (HOD), ASCO proposed four resolutions on step therapy, Medicare Part B drugs, a Competitive Acquisition Program, and clinical trial access, all of which were adopted or reaffirmed by the policy-making...
Breakthroughs Save Lives: ASCO’s Conquer Cancer Foundation Launches National Awareness Campaign
“I realized I just couldn’t wait for a new treatment option,” a determined Breelyn Wilky, MD, says, staring into the camera. “I had to find one.” If you missed the debut of the “Breakthroughs Save Lives” video during the 2018 ASCO Annual Meeting, look for it on television and online as part of a...
Illustrating Genius
FOUR AND A HALF YEARS AGO, author Neil Canavan attended a scientific conference to learn what he could about the then-emerging field of immunotherapy for cancer. After a presentation by Zelig Eshhar, PhD, principal investigator in the Department of Immunology at the Weizmann Institute of Science...
Global Oncology Education and Professional Development: ASCO International’s Impact
ASCO is such a misnomer: the American Society of Clinical Oncology is far more than simply “American.” Over the past several years, I (a Canadian-born breast surgical oncologist, with an Indian-born mother and a Tanzanian-born father) have traveled to Zimbabwe, Bhutan, and the Philippines with this ...
FDA Announces New Updates to Expanded Access Program
The U.S. Food and Drug Administration (FDA) recently announced new changes to expand and update the Expanded Access (EA) program, which allows very ill patients access to experimental treatments outside of clinical trials. The most recent updates include: Clarifications on Safety Data: The FDA...
Apply to Join ASCO’s Education Council by January 31
ASCO is seeking leaders in education to join its Education Council. The Council consists of ASCO members who are committed to advancing ASCO’s educational mission. Specific responsibilities of the Council include prioritizing programs to address educational gaps, advising on the latest in...
Clinician Survey to Explore Direct-Acting Oral Anticoagulants vs Low–Molecular-Weight Heparin in Cancer-Related VTE
Injectable low–molecular-weight heparin has long been considered the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. However, low–molecular-weight heparin is costly and often disliked by patients due to injection-related discomfort and bruising....
Check Out the Top Five Most Popular ASCO University Courses of 2018
New to ASCO University’s e-learning offerings and not sure where to start? With a comprehensive course catalog that spans tumor types, practice information, and other aspects of cancer care, choosing a course can be a challenge. To help get you started, here is a list of the most popular courses of ...
Improving Palliative Care in Low-Resource Settings
In 2016, ASCO published an update to its Clinical Practice Guideline, “Integration of Palliative Care Into Standard Oncology Care,” which provides evidence-based recommendations for symptom management, clarification of treatment goals, support of coping and distress management, and coordination of...
Study Findings on Myeloproliferative Neoplasms Including Systemic Mastocytosis
HERE IS AN UPDATE on six different studies featured at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focused on novel treatments for myelofibrosis, polycythemia vera and essential thrombocythemia, as well as systemic mastocytosis. Myelofibrosis ABSTRACT...
Lorlatinib in Second- or Third-Line Treatment of ALK-Positive Metastatic Non–Small Cell Lung Cancer
On November 2, 2018, lorlatinib (Lorbrena) was granted accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) whose disease has progressed on crizotinib (Xalkori) and at least one other ALK inhibitor for metastatic disease or whose disease ...
